




International Journal of Gerontology

journal homepage: <http://www.sgecm.org.tw/ijge/>



CME for 13.2

1. Compared with brand-name drugs, generic drugs are:
 - (A) With the same safety profile in the real world practice
 - (B) With the same effectiveness in the real world practice
 - (C) Able to 1:1 switch without further monitoring
 - (D) Tested with bioavailability and bioequivalence in healthy volunteers
 - (E) With completely the same major and minor components
2. According this article, after switch from brand-name glimepiride to generic one, which of the following statements is **NOT** true?
 - (A) The HbA1c was not substantially changed
 - (B) Most of patients changed either their dosage or hypoglycemics
 - (C) The patients with unchanged medication before and after switch tended to have higher HbA1c
 - (D) The confounding factors of this study have been well-controlled
 - (E) This study is a retrospective electronic medical record analysis
3. Which of the following statements regarding prescribed daily dose (PDD) and defined daily dose (DDD) are **NOT** true?
 - (A) DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults
 - (B) PDD is the average dose prescribed to a population of patients
 - (C) DDD does not necessarily reflect the PDD or recommended doses
 - (D) PDD/DDD ratio reflects the gap between PDD and DDD and may be influenced by disease severity
 - (E) PDD/DDD ratio is irrelevant to pharmacoeconomics
4. In this study, authors observed that PDD/DDD ratio after the switch from brand-name to generic glimepiride:
 - (A) Significantly increased in the group that changed the medication
 - (B) Significantly decreased in the group that changed the medication
 - (C) Significantly decreased in the group that maintained the medication
 - (D) Significantly increased in the group that maintained the medication
 - (E) No significant change in both groups
5. After switching a drug from brand-name to generic one, which of the following actions is inappropriate?
 - (A) Regular monitoring the compliance of patients
 - (B) Regular follow-up for the related laboratory data
 - (C) Regular contact the generic pharmaceutical company to pursue cost reduction
 - (D) Regular monitoring adverse reactions in patients
 - (E) Regular monitoring quality and stability of the drugs switched

Issue date: June 1st, 2019

Expiration date: September 30th, 2019

Volume 13 Issue 1 Answers:

1. (E)
2. (C)
3. (E)
4. (D)
5. (E)